<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597790</url>
  </required_header>
  <id_info>
    <org_study_id>12-001792 (CTSI-PLACE)</org_study_id>
    <secondary_id>N/A (Parent P30AI028697)</secondary_id>
    <secondary_id>N/A (Parent UL1TR000124)</secondary_id>
    <secondary_id>52767</secondary_id>
    <nct_id>NCT02597790</nct_id>
  </id_info>
  <brief_title>A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects</brief_title>
  <acronym>CTSI-PLACE</acronym>
  <official_title>Clinical and Translational Science Institute Prospective Longitudinal Assessment of Coinfected Subjects With HIV/Hepatitis C for Endothelial Function Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CTSI-PLACE Study is a study for men and women with HIV/hepatitis C co-infection or HIV
      only. The study looks at the impact of having hepatitis C virus in addition to HIV on risk
      for cardiovascular disease. Participants will undergo non-invasive assessment of
      cardiovascular disease risk through measurements of endothelial function and blood biomarkers
      at baseline and 1 year (or 4 weeks and 24 weeks after end of HCV treatment for those that
      undergo HCV treatment during study follow-up).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive hyperemia index (RHI) by peripheral arterial tonometry (PAT)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soluble biomarkers (fasting lipid panel, hsCRP, IL-6, D-dimer, sICAM-1, sE-selectin, Lp-PLA2, sCD14, sCD163)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive hyperemia index (RHI)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble biomarkers (fasting lipid panel, hsCRP, IL-6, D-dimer, sICAM-1, sE-selectin, Lp-PLA2, sCD14, sCD163)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by HOMA-IR</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance by HOMA-IR</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham risk score (FRS)</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham risk score (FRS)</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RHI</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of each soluble biomarker (components of fasting lipid panel, hsCRP, IL-6, D-dimer, sICAM-1, sE-selectin, Lp-PLA2, sCD14, sCD163)</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FRS</measure>
    <time_frame>Baseline to Week 52</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group A (HIV/HCV coinfected)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (HIV monoinfected)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV/HCV coinfected and HIV monoinfected adults with well-controlled HIV
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Men and women â‰¥ 18 years

          2. Hepatitis C negative or chronic hepatitis C infection

          3. Chronic HIV infection

          4. CD4+ T-cell count &gt; 200 cells/mm3

          5. Plasma HIV-1 RNA &lt; 50 copies/mL

          6. On continuous and stable ART for at least 12 weeks

          7. Ability and willingness to provide written informed consent.

        Exclusion Criteria

          1. Known cardiovascular disease

          2. Diabetes requiring insulin therapy or hemoglobin A1c &gt; 8%

          3. Inability to conform to requirements for PAT testing

          4. Decompensated liver disease

          5. Other known causes of significant liver disease

          6. Serious illness including acute liver-related disease and malignancy requiring
             systemic treatment or hospitalization within 12 weeks prior to study entry

          7. Presence of active or acute AIDS-defining opportunistic infections (OIs) within 12
             weeks prior to study entry

          8. History of major organ transplantation with an existing functional graft and on
             immunosuppressive therapy

          9. History of known vascular or autoimmune disease

         10. Pregnancy

         11. HCV treatment (any approved or investigational agents) within 24 weeks prior to study
             entry

         12. Use of immune-based therapies or systemic corticosteroids within 12 weeks prior to
             study entry

         13. Advanced renal insufficiency as defined by glomerular filtration rate (GFR) &lt; 30
             mL/min/1.73 m2 or treatment by dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara W. Chew, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara W. Chew, M.D., M.S.</last_name>
    <phone>310-825-6689</phone>
    <email>kchew@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irma Franco-Gonzalez</last_name>
    <phone>310-825-6689</phone>
    <email>ifranco@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malini Gandhi</last_name>
      <phone>310-825-7907</phone>
      <email>mgandhi@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arezou S Akha</last_name>
      <phone>310-557-9062</phone>
      <email>asadighi@mednet.ucla.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Kara Chew</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>metabolic disease</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

